{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:45:02Z","timestamp":1784141102782,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Key Research Projects of Henan Higher Education Institutions","award":["20A320057"],"award-info":[{"award-number":["20A320057"]}]},{"name":"Medical Science and Technology Project of Henan Province","award":["LHGJ20190004"],"award-info":[{"award-number":["LHGJ20190004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Intravascular large B-cell lymphoma (IVLBCL) is a rare, aggressive lymphoma characterized by lymphoma cells proliferating within small blood vessels, lacking an extravascular mass. Its low incidence complicates diagnosis and treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study analyzed 20 IVLBCL patients diagnosed between 2018 and 2024, aiming to describe their clinical presentations, diagnostic procedures, treatment, and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All patients had stage IV disease with poor ECOG performance status and high-risk IPI scores (100%\u2005\u2265\u20054). Common symptoms included fever (65%), impaired consciousness (30%), and respiratory issues (25%). Laboratory findings revealed cytopenias (60% anemia, 60% thrombocytopenia, and 35% leukocytopenia), elevated lactate dehydrogenase (20\/20, 100%), C-reactive protein (14\/14, 100%), and erythrocyte sedimentation rate (11\/12, 91.7%). Five of six patients had extreme IL-10 elevation. Imaging studies showed a high incidence of adrenal gland involvement (9\/20, 45%), reproductive system involvement (7\/20, 35%), central nervous system (CNS) involvement (6\/20, 30%), and splenomegaly (9\/20, 45%). Nineteen of 20 patients were non-GCB (CD10-MUM1+). Seven of 14 patients tested positive for CD5. Eighteen of 20 patients received CD20 antibody plus chemotherapy as first-line therapy, with complete responses (CRs) achieved in 7 of 18 patients. After a median follow-up of 42.4 months, the 1-year and 2-year overall survival rates were 71.3% and 65.4%, respectively. Unfavorable risk factors included central nervous system (CNS) and bone marrow (BM) involvement, and elevated creatinine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The study highlights the high incidence of adrenal and reproductive system involvement in IVLBCL, with CNS, BM, and elevated creatinine contributing to rapid disease progression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf156","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T23:14:08Z","timestamp":1751066048000},"source":"Crossref","is-referenced-by-count":7,"title":["Clinical features and prognostic factors of intravascular large B-cell lymphoma: a cohort study of 20 patients from 2018 to 2024"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4672-9010","authenticated-orcid":false,"given":"Yaqing","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University , 450052 Zhengzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University , 450052 Zhengzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University , 450052 Zhengzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University , 450052 Zhengzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University , 450052 Zhengzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University , 450052 Zhengzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University , 450052 Zhengzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-6090","authenticated-orcid":false,"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University , 450052 Zhengzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"2025062719140418300_CIT0001","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1200\/JCO.2006.08.2313","article-title":"Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting","volume":"25","author":"Ponzoni","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025062719140418300_CIT0002","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1182\/blood-2017-04-737445","article-title":"Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks","volume":"132","author":"Ponzoni","year":"2018","journal-title":"Blood"},{"key":"2025062719140418300_CIT0003","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-8722-4-14","article-title":"Frequency of intravascular large B-cell lymphoma in Japan: study of the Osaka Lymphoma Study Group","volume":"4","author":"Chihara","year":"2011","journal-title":"J Hematol Oncol"},{"key":"2025062719140418300_CIT0004","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/bjh.16081","article-title":"Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years","volume":"187","author":"Matsue","year":"2019","journal-title":"Br J Haematol"},{"key":"2025062719140418300_CIT0005","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(09)70140-8","article-title":"Presentation and management of intravascular large B-cell lymphoma","volume":"10","author":"Shimada","year":"2009","journal-title":"Lancet Oncol"},{"key":"2025062719140418300_CIT0006","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2141.2004.05177.x","article-title":"Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the \u201ccutaneous variant","volume":"127","author":"Ferreri","year":"2004","journal-title":"Br J Haematol"},{"key":"2025062719140418300_CIT0007","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/DAD.0000000000000321","article-title":"Usefulness of random skin biopsy as a diagnostic tool of intravascular lymphoma presenting with fever of unknown origin","volume":"37","author":"Pongpudpunth","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"2025062719140418300_CIT0008","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/cup.12984","article-title":"Random skin biopsy in the diagnosis of intravascular lymphoma","volume":"44","author":"Sitthinamsuwan","year":"2017","journal-title":"J Cutan Pathol"},{"key":"2025062719140418300_CIT0009","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000476027","article-title":"Limited role of random skin biopsy in the diagnosis of intravascular lymphoma in adult patients with hemophagocytic lymphohistiocytosis","volume":"138","author":"Cho","year":"2017","journal-title":"Acta Haematol"},{"key":"2025062719140418300_CIT0010","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000437363","article-title":"Three cases of intravascular large b-cell lymphoma detected in a biopsy of skin lesions","volume":"232","author":"Arai","year":"2016","journal-title":"Dermatology"},{"key":"2025062719140418300_CIT0011","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3324\/haematol.10829","article-title":"Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions","volume":"92","author":"Ferreri","year":"2007","journal-title":"Haematologica"},{"key":"2025062719140418300_CIT0012","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1182\/blood-2006-01-021253","article-title":"Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5","volume":"109","author":"Murase","year":"2006","journal-title":"Blood"},{"key":"2025062719140418300_CIT0013","doi-asserted-by":"publisher","first-page":"e5985","DOI":"10.1097\/MD.0000000000005985","article-title":"Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: a retrospective study of 29 case reports","volume":"96","author":"Brunet","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"2025062719140418300_CIT0014","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1002\/ctm2.131","article-title":"Serum interleukin-10 as a valuable biomarker for early diagnosis and therapeutic monitoring in intravascular large B-cell lymphoma","volume":"10","author":"Zhang","year":"2020","journal-title":"Clin Transl Med"},{"key":"2025062719140418300_CIT0015","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1097\/RLU.0000000000002939","article-title":"\u201cHot Lung\u201d sign in pulmonary intravascular large B-cell lymphoma on 18F-FDG PET\/CT","volume":"45","author":"\u00d6zlem \u00d6zt\u00fcrk","year":"2020","journal-title":"Clin Nucl Med"},{"key":"2025062719140418300_CIT0016","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1158\/0008-5472.CAN-03-4056","article-title":"Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma","volume":"64","author":"Hiroyuki","year":"2004","journal-title":"Cancer Res"},{"key":"2025062719140418300_CIT0017","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00277-010-1101-3","article-title":"Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma","volume":"90","author":"Matsue","year":"2011","journal-title":"Ann Hematol"},{"key":"2025062719140418300_CIT0018","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1182\/blood-2018-11-887570","article-title":"Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma","volume":"133","author":"Matsue","year":"2019","journal-title":"Blood"},{"key":"2025062719140418300_CIT0019","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1182\/blood-2017-12-822817","article-title":"High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma","volume":"131","author":"Schrader","year":"2018","journal-title":"Blood"},{"key":"2025062719140418300_CIT0020","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"2025062719140418300_CIT0021","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/PAS.0000000000001978","article-title":"Intravascular large B-cell lymphoma genomic profile is characterized by alterations in genes regulating NF-kappaB and immune checkpoints","volume":"47","author":"Gonzalez-Farre","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"2025062719140418300_CIT0022","doi-asserted-by":"publisher","first-page":"10531","DOI":"10.2147\/CMAR.S267825","article-title":"Prognosis of Intravascular Large B Cell Lymphoma (IVLBCL): analysis of 182 patients from global case series","volume":"12","author":"Liu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"2025062719140418300_CIT0023","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1080\/10428194.2022.2123239","article-title":"Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL","volume":"63","author":"Terao","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2025062719140418300_CIT0024","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1182\/blood-2021-152417","article-title":"The interim analysis from a prospective single-center phase 2 study of zanubrutinib plus R-CHOP in treat-na\u00efve intravascular large B cell lymphoma","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood"},{"key":"2025062719140418300_CIT0025","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1200\/JCO.23.01574","article-title":"CD5 gene signature identifies diffuse large B-cell lymphomas sensitive to bruton\u2019s tyrosine kinase inhibition","volume":"42","author":"Cooper","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025062719140418300_CIT0026","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2007.15.4278","article-title":"Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan","volume":"26","author":"Shimada","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025062719140418300_CIT0027","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1002\/cam4.3104","article-title":"PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy","volume":"9","author":"Suzuki","year":"2020","journal-title":"Cancer Med"},{"key":"2025062719140418300_CIT0028","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/his.13870","article-title":"A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features","volume":"75","author":"Gupta","year":"2019","journal-title":"Histopathology"},{"key":"2025062719140418300_CIT0029","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/s0046-8177(00)80223-3","article-title":"Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis","volume":"31","author":"Ponzoni","year":"2000","journal-title":"Hum Pathol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf156\/63535547\/oyaf156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf156\/63535547\/oyaf156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T23:14:09Z","timestamp":1751066049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf156\/8169780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf156","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf156"}}